Avicanna Net Income
| AVCNF Stock | USD 0.13 0.01 7.14% |
As of the 12th of February 2026, Avicanna shows the Mean Deviation of 4.69, standard deviation of 6.77, and Risk Adjusted Performance of (0.01). Avicanna technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate thirteen technical drivers for Avicanna, which can be compared to its peers. Please confirm Avicanna coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Avicanna is priced correctly, providing market reflects its regular price of 0.13 per share. As Avicanna appears to be a penny stock we also recommend to validate its jensen alpha numbers.
Avicanna's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Avicanna's valuation are provided below:Avicanna does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Avicanna |
Avicanna 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Avicanna's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Avicanna.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Avicanna on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Avicanna or generate 0.0% return on investment in Avicanna over 90 days. Avicanna is related to or competes with Voyageur Pharmaceuticals, Charlottes Web, Raphael Pharmaceutical, and Izotropic. Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based p... More
Avicanna Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Avicanna's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Avicanna upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 39.08 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 11.76 |
Avicanna Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avicanna's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Avicanna's standard deviation. In reality, there are many statistical measures that can use Avicanna historical prices to predict the future Avicanna's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.99) | |||
| Treynor Ratio | 0.1436 |
Avicanna February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.1536 | |||
| Mean Deviation | 4.69 | |||
| Coefficient Of Variation | (3,781) | |||
| Standard Deviation | 6.77 | |||
| Variance | 45.85 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.99) | |||
| Treynor Ratio | 0.1436 | |||
| Maximum Drawdown | 39.08 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 11.76 | |||
| Skewness | 0.1394 | |||
| Kurtosis | 1.14 |
Avicanna Backtested Returns
Avicanna secures Sharpe Ratio (or Efficiency) of -0.0361, which signifies that the company had a -0.0361 % return per unit of risk over the last 3 months. Avicanna exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Avicanna's Risk Adjusted Performance of (0.01), standard deviation of 6.77, and Mean Deviation of 4.69 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.32, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Avicanna are expected to decrease by larger amounts. On the other hand, during market turmoil, Avicanna is expected to outperform it. At this point, Avicanna has a negative expected return of -0.24%. Please make sure to confirm Avicanna's total risk alpha and the relationship between the skewness and period momentum indicator , to decide if Avicanna performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.04 |
Virtually no predictability
Avicanna has virtually no predictability. Overlapping area represents the amount of predictability between Avicanna time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Avicanna price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Avicanna price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Avicanna reported net income of (16.77 Million). This is 104.92% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 102.94% higher than that of the company.
Avicanna Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avicanna's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Avicanna could also be used in its relative valuation, which is a method of valuing Avicanna by comparing valuation metrics of similar companies.Avicanna is currently under evaluation in net income category among its peers.
Avicanna Fundamentals
| Return On Equity | -1.69 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (2.11) % | |||
| Current Valuation | 20.15 M | |||
| Shares Outstanding | 74.52 M | |||
| Shares Owned By Insiders | 22.52 % | |||
| Price To Book | 9.32 X | |||
| Price To Sales | 4.51 X | |||
| Revenue | 3.27 M | |||
| Gross Profit | 2.83 M | |||
| EBITDA | (15.13 M) | |||
| Net Income | (16.77 M) | |||
| Cash And Equivalents | 685.94 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 415.83 K | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 0.90 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (11.66 M) | |||
| Earnings Per Share | (0.26) X | |||
| Number Of Employees | 124 | |||
| Beta | 1.94 | |||
| Market Capitalization | 22.99 M | |||
| Total Asset | 22.3 M | |||
| Z Score | 33.0 | |||
| Net Asset | 22.3 M |
About Avicanna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avicanna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avicanna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avicanna based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Avicanna OTC Stock
Avicanna financial ratios help investors to determine whether Avicanna OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avicanna with respect to the benefits of owning Avicanna security.